Statements (20)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
David Domzalski
|
| gptkbp:country |
gptkb:United_States
|
| gptkbp:developedBy |
therapies for inflammatory and immunological conditions
|
| gptkbp:focusesOn |
immunology
dermatology |
| gptkbp:formerName |
Menlo Therapeutics Inc.
|
| gptkbp:foundedYear |
2004
|
| gptkbp:headquartersLocation |
gptkb:Bridgewater,_New_Jersey,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
VYNE Therapeutics Inc.
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:notableProduct |
AMZEEQ
FCD105 ZILXI |
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
VYNE
|
| gptkbp:tradedOn |
NASDAQ: VYNE
|
| gptkbp:website |
https://www.vynetherapeutics.com/
|
| gptkbp:bfsParent |
gptkb:VYNT
|
| gptkbp:bfsLayer |
7
|